Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat alfa for prevention of contrast-induced nephropathy
NCT02869347Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conestat alfa in contrast-induced nephropathy (CIN), sponsored by University Hospital Basel. Started Jan 2017; status: completed.
02
Drugs
conestat alfa
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT02869347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869347.